3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
65
Neoplasms
29
Neoplasm Metastasis
11
Thyroid Neoplasms
10
Thyroid Carcinoma, Anaplastic
9
Glioma
9
Brain Neoplasms
9
Multiple Myeloma
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Hematologic Neoplasms
6
Thyroid Cancer, Papillary
4
Skin Neoplasms
4
Ameloblastoma
4
Histiocytosis, Langerhans-Cell
3
Glioblastoma
3
Astrocytoma
3
Rectal Neoplasms
2
Prostatic Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neurofibroma, Plexiform
2
Neurocytoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Ganglioneuroma
2
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
dabrafenib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled